Cannabidiol (CBD) as an Adjunctive Therapy in Schizophrenia: A Multicenter Randomized Controlled Trial

McGuire, Philip; Robson, Philip; Cubała, Wiesław Jerzy; Vasile, D.; Morrison, Paul; Barrón, Rachel; Taylor, Adam; Wright, Stephen

doi:10.1176/appi.ajp.2017.17030325

Cited by 506 publications

(437 citation statements)

References 22 publications

Supporting

Mentioning

407

Contrasting

Unclassified

Order By: Relevance

“…Seven studies were conducted in the context of schizophrenia and bipolar disorder. Within the RCTs, 2 conducted with an average dosing of 15 mg/kg/d over 4 or 8 weeks reported positive reductions in psychotic or psychiatric symptoms and a better side effect profile ( n = 130) . One of these compared CBD against an active control (amisulpride), and the other as an add‐on therapy to usual medication compared to placebo as an add‐on therapy.…”

Section: Resultsmentioning

confidence: 99%

A systematic review of cannabidiol dosing in clinical populations

Millar

Stone

Bellman

et al. 2019

Brit J Clinical Pharma

177

148

View full text Add to dashboard Cite

Aims Cannabidiol (CBD) is a cannabis‐derived medicinal product with potential application in a wide‐variety of contexts; however, its effective dose in different disease states remains unclear. This review aimed to investigate what doses have been applied in clinical populations, in order to understand the active range of CBD in a variety of medical contexts. Methods Publications involving administration of CBD alone were collected by searching PubMed, EMBASE and ClinicalTrials.gov . Results A total of 1038 articles were retrieved, of which 35 studies met inclusion criteria covering 13 medical contexts. Twenty‐three studies reported a significant improvement in primary outcomes (e.g. psychotic symptoms, anxiety, seizures), with doses ranging between <1 and 50 mg/kg/d. Plasma concentrations were not provided in any publication. CBD was reported as well tolerated and epilepsy was the most frequently studied medical condition, with all 11 studies demonstrating positive effects of CBD on reducing seizure frequency or severity (average 15 mg/kg/d within randomised controlled trials). There was no signal of positive activity of CBD in small randomised controlled trials (range n = 6–62) assessing diabetes, Crohn's disease, ocular hypertension, fatty liver disease or chronic pain. However, low doses (average 2.4 mg/kg/d) were used in these studies. Conclusion This review highlights that CBD has a potential wide range of activity in several pathologies. Pharmacokinetic studies as well as conclusive phase III trials to elucidate effective plasma concentrations within medical contexts are severely lacking and highly encouraged.

show abstract

Section: Resultsmentioning

confidence: 99%

A systematic review of cannabidiol dosing in clinical populations

Millar

Stone

Bellman

et al. 2019

Brit J Clinical Pharma

177

148

View full text Add to dashboard Cite

show abstract

“…Finally, McGuire et al . have performed a large randomized double‐blind controlled trial study in patients with schizophrenia who received treatment of CBD vs. patients with schizophrenia who received placebo alongside their on‐going antipsychotic medications.…”

Section: Acute and Long‐term Effectsmentioning

confidence: 89%

“…Although a large body of knowledge indicates the negative effect that cannabinoids have on psychological function, contemporary research has investigated the therapeutic potential of exogenous cannabinoids, such as CBD and nabilone, a synthetic cannabinoid for mental disorders, such as schizophrenia, posttraumatic stress disorder (PTSD), general and social anxiety, and it has suggested some promising future directions . Crippa et al .…”

Section: Acute and Long‐term Effectsmentioning

confidence: 99%

Positive and Negative Effects of Cannabis and Cannabinoids on Health

Cohen

Weizman

Weinstein

2019

Clin Pharma and Therapeutics

195

128

View full text Add to dashboard Cite

Cannabis is the most popular illicit drug in the Western world. Repeated cannabis use has been associated with short‐ and long‐term side effects, including respiratory and cardiovascular disorders, cognitive alterations, psychosis, schizophrenia, and mood disorders. However, casual relations between cannabis use and these adverse effects are missing. On the other hand, recent research proposed promising therapeutic potential of cannabinoid‐based drugs for a wide range of medical conditions, including neurological and psychiatric disorders. The current article presents a contemporary review on the adverse effects, safety, and the therapeutic potential of cannabis and cannabinoid‐based drugs. Given the growing popularity in the use of cannabinoid‐based drugs for both recreational and medical purposes and their potential harmful effects, there is a need for further investigation in this field.

show abstract

“…The media attention generated by its effect on severely ill children gave CBD the push needed to become a much desired medicine almost overnight [11]. Other medical indications that may be treated with CBD, and are supported to some extent by clinical proof, include Parkinson's disease [12], schizophrenia [13], and anxiety disorder [14]. However, although research into the therapeutic effects of CBD is rapidly increasing, most current uses of CBD are not (yet) supported by clinical data.…”

Section: Therapeutic Effects Of Cbdmentioning

confidence: 99%

The Trouble with CBD Oil

Hazekamp¹

2018

Med Cannabis Cannabinoids

157

129

View full text Add to dashboard Cite

In just a few years, cannabidiol (CBD) has become immensely popular around the world. After initially being discovered as an effective self-medication for Dravet syndrome in children, CBD is now sold and used to treat a wide range of medical conditions and lifestyle diseases. The cannabinoid CBD, a non-psychoactive isomer of the more infamous tetrahydrocannabinol (THC), is available in a growing number of administration modes, but the most commonly known is CBD oil. There are currently dozens, if not hundreds, of producers and sellers of CBD oils active in the market, and their number is increasing rapidly. Those involved vary from individuals who prepare oils on a small scale for family and (Facebook) friends to compounding pharmacies, pharmaceutical companies, and licensed cannabis producers. Despite the growing availability of CBD, many uncertainties remain about the legality, quality, and safety of this new “miracle cure.” As a result, CBD is under scrutiny on many levels, ranging from national health organizations and agricultural lobbyists to the WHO and FDA. The central question is whether CBD is simply a food supplement, an investigational new medicine, or even a narcotic. This overview paper looks into the known risks and issues related to the composition of CBD products, and makes recommendations for better regulatory control based on accurate labeling and more scientifically supported health claims. The intention of this paper is to create a better understanding of the benefits versus the risks of the current way CBD products are produced, used, and advertised.

show abstract

Cannabidiol (CBD) as an Adjunctive Therapy in Schizophrenia: A Multicenter Randomized Controlled Trial

Abstract: These findings suggest that CBD has beneficial effects in patients with schizophrenia. As CBD's effects do not appear to depend on dopamine receptor antagonism, this agent may represent a new class of treatment for the disorder.

Cited by 506 publications

References 22 publications

A systematic review of cannabidiol dosing in clinical populations

A systematic review of cannabidiol dosing in clinical populations

Positive and Negative Effects of Cannabis and Cannabinoids on Health

The Trouble with CBD Oil

Contact Info

Product

Resources

About